MorphoSys AG
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MorphoSys AG, a commercial-stage biopharmaceutical company, discovers, develops and commercializes therapeutic antibodies primarily for cancer and autoimmune diseases using proprietary technologies including HuCAL and OkapY bispecific formats; key products comprise tafasitamab (Monjuvi), approved for relapsed or refractory diffuse large B-cell lymphoma in combination with lenalidomide, partnered with Incyte Corporation, as well as pelabresib from its 2021 acquisition of Constellation Pharmaceuticals and earlier-stage candidates like felzartamab targeting CD38 for kidney disease and otilimab licensed to GlaxoSmithKline for rheumatoid arthritis. The company maintains a broad pipeline exceeding 100 candidates, many partnered with firms such as Janssen (guselkumab/Tremfya for psoriasis), Novartis, Roche and Pfizer, focusing on oncology and hematology segments for patients with unmet needs. Founded in 1992 and headquartered in Planegg near Munich, Germany, with a wholly owned subsidiary MorphoSys US Inc. in Boston, Massachusetts, it operates globally across Europe and the United States. In 2024, Novartis agreed to acquire MorphoSys for EUR 2.7 billion at EUR 68 per share, completed a voluntary public takeover reaching over 91% ownership, approved a merger squeeze-out of minority shareholders at its August annual general meeting and delisted from the Frankfurt Stock Exchange and Nasdaq, integrating its assets into Novartis' oncology pipeline.
Contrasting Scopus BioPharma (NASDAQ:SCPS) & MorphoSys (NASDAQ:MOR)
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
Novartis: launch of Morphosys drug by could be 2027 or later
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG – MOR
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG's Minority Shareholders
The State of Massachusetts Issues MOR-EV Approval, Granting Mullen's Class 3 EV Truck a $15,000 Cash Voucher per Vehicle Sold
MorphoSys AG Forecasted to Post Q2 2024 Earnings of ($0.54) Per Share (NASDAQ:MOR)
Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN)
MorphoSys: Hold Rating Until The Novartis Deal Closes
MorphoSys AG Reports First Quarter 2024 Financial Results
Morphosys says Novartis takeover progressing as planned for H1 2024
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis